The acronym ROADMAP stands for: “Real world Outcomes across the Alzheimer’s Disease spectrum for better care: Multi-modal data Access Platform”.
Phase 1 of ROADMAP began in November 2016 and lasts for two years. October 2017, therefore, marks the halfway point of the project.
In Phase 1 ROADMAP’s goal is to lay the foundation of an EU-wide data sharing space for real-world evidence (RWE) outcomes for better care in Alzheimer's disease.
By the end of October 2018, the ROADMAP consortium, a public private collaboration of 25 partners from Europe, coordinated by the University of Oxford and Novartis, aims to deliver guiding principles and recommendations on integrating available RWE to support healthcare decision making in AD treatment and research.